Kyverna Therapeutics (KYTX) financial statements
Net income was -$161M.
Free cash flow was -$155M.
The diluted share count rose 6470% over the period (dilution).
Income statement
Fiscal years, from Kyverna Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Research and development | $50M | $112M | $134M |
| Selling, general and admin | $12M | $30M | $36M |
| Operating income | -$62M | -$143M | -$170M |
| Interest expense | $187,000 | $142,000 | $489,000 |
| Income tax | $0 | $0 | $0 |
| Net income | -$60M | -$127M | -$161M |
| EPS (diluted) | -$89.61 | -$3.33 | -$3.64 |
| Diluted shares | 1M | 38M | 44M |
Balance sheet
Fiscal years, from Kyverna Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $58M | $286M | $279M |
| Total current assets | $61M | $291M | $283M |
| Property, plant and equipment | $2M | $3M | $2M |
| Total assets | $75M | $305M | $294M |
| Total current liabilities | $20M | $34M | $36M |
| Long-term debt | — | — | $25M |
| Total liabilities | $26M | $38M | $62M |
| Shareholders' equity | -$13M | $267M | $232M |
| Net debt | -$35M | -$97M | -$99M |
Cash flow
Fiscal years, from Kyverna Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -$52M | -$114M | -$154M |
| Capital spending | $621,000 | $2M | $1M |
| Free cash flow | -$53M | -$116M | -$155M |
| Stock-based compensation | $2M | $8M | $10M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for KYTX.
Open KYTX in InvestinglyQuestions
How much free cash flow does Kyverna Therapeutics generate?
-$155M in fiscal 2025 (operating cash flow minus capital spending).
From Kyverna Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.